Dose to pelvic lymph nodes in image based high dose rate brachytherapy of carcinoma cervix

被引:5
作者
Rangarajan, Ramya [1 ]
Subramanian, Saravanan [1 ]
Gopalakrishnan, Kalyani [1 ]
Jothi, Vijayalakshmi [1 ]
Krishnamurthy, Kumari [1 ]
机构
[1] Govt Royapettah Hosp, Dept Radiat Oncol, Chennai, India
关键词
Lymph node dose; Intracavitary brachytherapy; CT based planning; CONCURRENT CHEMOTHERAPY; INVASIVE CARCINOMA; RADIATION; CANCER; IRRADIATION; RADIOTHERAPY; COMBINATION; DELINEATION; GUIDELINES; CISPLATIN;
D O I
10.1016/j.rpor.2018.10.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of this study is to analyse the dosimetry to the pelvic lymph nodes and its correlation to point B using CT based high dose rate brachytherapy of carcinoma cervix. Background: Conventionally, dose to pelvic lymph nodes from intracavitary brachytherapy was reported by point B and by the reference points of the lymphatic trapezoid. Materials and methods: 30 consecutive CT based high dose rate applications were reviewed between February and March 2016. The high risk clinical target volume and the organs at risk and the pelvic nodal groups were contoured. DVH parameters for the right and left obturator nodal group, right and left external iliac nodal group and right and left internal iliac nodal group were recorded. Right and left point B doses were also recorded. Results: On analysis of the combined dose, it was found that all the DVH parameters were significantly different from point B, except the D100 obturator and D2cc internal iliac lymph node. There was a significant correlation between all DVH parameters and point B, except D2cc, D1cc and D0.1cc of external iliac. The obturator group received the highest dose contribution from brachytherapy. The mean D90 dose received per fraction for the obturator, external iliac and internal iliac nodes was 2.7 Gy, 1.17 Gy and 1.41 Gy, respectively. Conclusions: There is a significant dose contribution to the pelvic lymph nodal groups during intracavitary brachytherapy. There is a low degree of correlation between point B dose and dosimetric parameters of the individual nodal groups. Hence, it is important to analyse the dose delivered to individual nodal groups during intracavitary brachytherapy, at least in patients with enlarged lymph nodes to calculate the cumulative dose delivered. (C) 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 24 条
[1]  
[Anonymous], 1980, TXB RADIOTHERAPY
[2]   Contribution of image-guided adaptive brachytherapy to pelvic nodes treatment in locally advanced cervical cancer [J].
Bacorro, Warren ;
Dumas, Isabelle ;
Levy, Antonin ;
Del Campo, Eleonor Rivin ;
Canova, Charles-Henri ;
Felefly, Tony ;
Huertas, Andres ;
Marsolat, Fanny ;
Haie-Meder, Christine ;
Chargari, Cyrus ;
Mazeron, Renaud .
BRACHYTHERAPY, 2017, 16 (02) :366-372
[3]   SURVIVAL AND PATTERNS OF RECURRENCE IN CERVICAL-CANCER METASTATIC TO PERIAORTIC LYMPH-NODES - (A GYNECOLOGIC ONCOLOGY GROUP-STUDY) [J].
BERMAN, ML ;
KEYS, H ;
CREASMAN, W ;
DISAIA, P ;
BUNDY, B ;
BLESSING, J .
GYNECOLOGIC ONCOLOGY, 1984, 19 (01) :8-16
[4]   SURGICAL + RADIATION TREATMENT OF INVASIVE CARCINOMA OF UTERINE CERVIX .3. SURGERY + RADIOTHERAPY FOR INVASIVE CANCER OF CERVIX [J].
CHRISTENSEN, A ;
NIELSEN, E ;
LANGE, P .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1964, 43 :59-+
[5]   Assessing dose contribution to pelvic lymph nodes in intracavitary brachytherapy for cervical cancer [J].
Chua, Gail Wan Ying ;
Foo, Yong Wee ;
Toy, Guan Heng ;
Tan, David Boon Horn .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2017, 9 (04) :345-353
[6]  
Denny L, 2012, DISCOV MED, V14, P125
[7]   Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01 [J].
Eifel, PJ ;
Winter, K ;
Morris, M ;
Levenback, C ;
Grigsby, PW ;
Cooper, J ;
Rotman, M ;
Gershenson, D ;
Mutch, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :872-880
[8]   SURGICAL PREDICTORS OF PARAAORTIC METASTASES IN EARLY-STAGE CERVICAL-CARCINOMA [J].
HACKETT, TE ;
OLT, G ;
SOROSKY, JI ;
PODCZASKI, E ;
HARRISON, TA ;
MORTEL, R .
GYNECOLOGIC ONCOLOGY, 1995, 59 (01) :15-19
[9]   Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A gynecologic oncology group study [J].
Lanciano, R ;
Calkins, A ;
Bundy, BN ;
Parham, G ;
Lucci, JA ;
Moore, DH ;
Monk, BJ ;
O'Connor, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8289-8295
[10]   CORRELATION OF POINT B AND LYMPH NODE DOSE IN 3D-PLANNED HIGH-DOSE-RATE CERVICAL CANCER BRACHYTHERAPY [J].
Lee, Larissa J. ;
Sadow, Cheryl A. ;
Russell, Anthony ;
Viswanathan, Akila N. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :803-809